Skip to content
The Policy VaultThe Policy Vault

Orilissa — Point32Health

moderate to severe pain associated with endometriosis

Initial criteria

  • Patient age ≥ 18 years
  • Patient has moderate to severe pain associated with endometriosis
  • Patient has had an insufficient response or intolerance to both of the following: oral nonsteroidal anti-inflammatory drugs (NSAIDs) AND hormonal contraceptive

Approval duration

Orilissa 200 mg: 6 months; Orilissa 150 mg: 24 months; total ≤ 24 months; Myfembree: 24 months